Posts Tagged ‘Cypher’

June 15th, 2011

Johnson & Johnson Steps Out of the Stent Market

Johnson & Johnson announced today that it is exiting the stent business. The company will discontinue development of its Nevo sirolimus-eluting stent and will end sales of its Cypher family of stents by the end of the year. The company was the manufacturer of both the first stent, the Palmaz-Schatz stent, in the 1990s and […]

May 24th, 2011

Stent BioWars: Erode or Absorb?


In January 2011, we blogged about ABSORB, a  bioresorbable stent, when it received CE approval for use in Europe. Drug-eluting stents (DES) are composed of a metal scaffold that is coated with a polymer containing an antiproliferative agent , which is released gradually over the weeks to months after the stent is inserted.  The durable polymer residue has […]

September 27th, 2010

Xience V Holds Its Own With Sirolimus-Eluting Stents

In the trials presented on Thursday at TCT, the everolimus-eluting Xience V stent (EES) proved superior to the paclitaxel-eluting Taxus stent at 2 years. But, as Gregg Stone  discussed here recently, a more formidable comparator for EES are the sirolimus-eluting stents (SES). Two trials presented on Friday demonstrated that EES are comparable in efficacy to SES. […]